Flavonoids are widely distributed phytochemicals in vegetables, fruits and medicinal plants. Recent studies demonstrate that some natural flavonoids are potent inhibitors of the human UDP-glucuronosyltransferase 1A1 (UGT1A1), a key enzyme in detoxification of endogenous harmful compounds such as bilirubin. In this study, the inhibitory effects of 56 natural and synthetic flavonoids on UGT1A1 were assayed, while the structure-inhibition relationships of flavonoids as UGT1A1 inhibitors were investigated. The results demonstrated that the C-3 and C-7 hydroxyl groups on the flavone skeleton would enhance UGT1A1 inhibition, while flavonoid glycosides displayed weaker inhibitory effects than their corresponding aglycones. Further investigation on inhibition kinetics of two strong flavonoid-type UGT1A1 inhibitors, acacetin and kaempferol, yielded interesting results. Both flavonoids were competitive inhibitors against UGT1A1-mediated NHPN-O-glucuronidation, but were mixed and competitive inhibitors toward UGT1A1-mediated NCHN-O-glucuronidation, respectively. Furthermore, docking simulations showed that the binding areas of NHPN, kaempferol and acacetin on UGT1A1 were highly overlapping, and convergence with the binding area of bilirubin within UGT1A1. In summary, detailed structure-inhibition relationships of flavonoids as UGT1A1 inhibitors were investigated carefully and the findings shed new light on the interactions between flavonoids and UGT1A1, and will contribute considerably to the development of flavonoid-type drugs without strong UGT1A1 inhibition.
A C C E P T E D M A N U S C R I P T
Introduction
Flavonoids are polyphenolic phytochemicals that are commonly present in the human diet, since they are abundant in vegetables, fruits, and a wide variety of other edible plants [1] [2] [3] . As an important class of bioactive compounds, flavonoids display many beneficial effects on human health, such as antioxidant, anti-inflammatory, anti-proliferative, anti-tumor, anti-microbial, and estrogenic-like activities, as well as regulatory effects on various enzymes [4] [5] [6] [7] [8] . Flavonoids-containing herbs, beverages (such as tea and coffee) or dietary supplements are often used for the prevention of various human diseases, such as diabetes, osteoporosis and cancer that are caused by free-radical damage, and as adjuvant treatment for liver injury, cardiovascular diseases and neurodegenerative disorders [9] [10] [11] [12] . (such as baicalin and sliymarin) have been widely used for treatment of hepatitis [13] [14] .
Meanwhile, some natural flavones (such as oroxylin A, wogonin and vitexin) are undergoing phase I/II clinical trials in China, for auxiliary treatment of cancer or coronary heart diseases [15] [16] [17] .
It is well-accepted that the drug-drug interaction potentials should be carefully investigated
ACCEPTED MANUSCRIPT
A C C E P T E D M A N U S C R I P T 5 during preclinical development process of drug candidates [18] [19] . Over the past twenty-years, many studies have been conducted to explore the regulatory effects of natural and synthetic flavones on drug metabolizing enzymes or transporters [20] [21] [22] . The results demonstrated that several polyphenolic flavones (such as baicalein and diosmetin) can strongly inhibit the activities of some human cytochrome P450 enzymes (CYPs), while other polymethoxylated flavones (such as tangeretin and nobiletin) are potent inhibitors of the multidrug transporter P-glycoprotein [23] [24] [25] [26] [27] . These investigations suggested that flavones could reduce the elimination of many therapeutic drugs that are substrates for CYPs or P-glycoprotein, thereby causing clinically relevant herb/food-drug interactions (HDIs) [28] .
The inhibitory effects of natural and synthetic flavones against phase II metabolizing enzymes, however, were rarely reported. This is somewhat surprising, considering that many flavones are substrates for phase II metabolizing enzymes such as the UDP-glucuronosyltransferases (UGTs) [29] [30] . As UGTs substrates, flavones could lead to undesirable effects via competitive inhibition by occupying the ligand-binding pockets in the substrate domain of the UGT enzymes [31] .
Mammalian UDP-glucuronosyltransferases are important endoplasmic reticulum-bound enzymes, which catalyze the conjugation of the glucuronic acid moiety from the donor UDP-glucuronic acid (UDPGA) to a variety of compounds, thus forming water-soluble glucuronides that are more easily eliminated [32] [33] . In human, there are over twenty different UGTs and the majority of them are expressed in the liver and/or the small intestine [33] [34] [35] . Among all known human UGTs, UGT1A1 is of particular importance due to its crucial role in the metabolic elimination and detoxification of bilirubin, a major product of
A C C E P T E D M A N U S C R I P T 6 hemoglobin metabolism, as well as several clinical drugs like cancer chemotherapy drug etoposide, the topoisomerase inhibitor SN-38 (the active metabolite of CPT-11), and the anti-AIDS agent raltegravir [36] [37] [38] [39] .
Impairment or considerable inhibition of UGT1A1 activity may lead to disorders in bilirubin metabolism, such as hyperbilirubinemia and jaundice, which may also be triggered by significant drug/herb-drug interactions (DDIs or HDIs) [40] [41] [42] . Previous studies have demonstrated that both therapeutic drugs and natural flavonoid-containing compounds in herbs or foods, including indinavir, erlotinib, regorafenib, licochalcone A, bavachin, corylifol A, and amentoflavone can strongly inhibit the catalytic activities of UGT1A1, thereby reduce bilirubin elimination and trigger clinically relevant drug-drug interactions [43] [44] [45] [46] [47] [48] . Thus, it is important to systematically assay the inhibitory effects of flavonoids on the human UGT1A1 and to explore structure-inhibition relationships among them with respect to UGT1A1 inhibition. Such an investigation will be valuable for developing new flavonoid-type drugs with improved safety profiles, and for avoiding or minimizing the occurrence of adverse side effects via UGT1A1 inhibition by flavonoids-containing products.
In the present study, more than fifty flavonoids were collected and their inhibitory effects on the human UGT1A1 were investigated carefully. A florescence-based biochemical assay was constructed for high-throughput screening of UGT1A1 inhibitors, in which the newly developed fluorescent substrate for UGT1A1 was used as a probe [47, [49] [50] and human liver microsomes (HLM) as the enzyme source. The potential structure-inhibition relationships of these structurally diverse flavonoids have been summarized and discussed. In
A C C E P T E D M A N U S C R I P T 7 order to deepen our understanding of the interactions between flavonoids and UGT1A1, the inhibition kinetics of acacetin and kaempferol, the most potent UGT1A1 inhibitors among all tested flavonoids, were carefully examined, using two different probe substrates for UGT1A1.
Our results strongly support the need to investigate the inhibitory effects of natural flavones and their derivatives toward human UGTs, especially those that are responsible for the elimination of endogenous toxins or clinical drugs with narrow therapeutic windows [32, [51] [52] . Wang), the synthetic details and structural characterization of these compounds were described previously [54] . Norwogonin and 8-methoxykaempferol were purchased from ChemFaces (Wuhan, China). Isorhamnetin, eupatilin, icaritin, fisetin, and morin were purchased from Sichuan Weikeqi Biotechnology Company (Chengdu, Sichuan, China). Other flavonoids that were used in this study were purchased from Chengdu Pufei De Biotech Co.,
Material and methods

Chemicals and reagents
Ltd. (Chengdu, Sichuan, China). The flavonoids purity was above 98% by LC-UV analysis.
All other reagents were of HPLC grade or of the highest grade commercially available.
Florescence-based enzyme inhibition assay 2.2.1 NCHN-O-glucuronidation based inhibition assay
The inhibitory effects of flavonoids on NCHN glucuronidation by the human UGT1A1, 
NHPN-O-glucuronidation based inhibition assay
The analyses were ranged from 1 and 100 µM. All incubations, from preincubation to termination and subsequent centrifugation, were carried out as described above for NCHN O-glucuronidation, and the fluorescence determination of NHPN concentration was carried out as previously described [42, [46] [47] . NHPN and each of the flavonoids were dissolved in DMSO, at a final concentration of 1% (v/v).
Inhibition kinetic analyses
The V=
where V is the velocity of the reaction; V max is the maximum velocity; S and I are the substrate and inhibitor concentrations, respectively; K m is the Michaelis constant (substrate concentration at 0.5 V max ); K i is the inhibition constant describing the affinity of the inhibitor towards the target enzyme (UGT1A1).
Molecular docking simulations
A knowledge-based comparative modelling method (SYBYL Advanced Protein Modeling Package) was used to construct a 3D structure of UGT1A1. Using the ORCHESTRAR
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11 module in the APM software package, we established a full-atom model of UGT1A1 that is based on the amino acid sequence of the enzyme and several known structural homologues.
The Homo sapiens sequence of UGT1A1 (accession number NP_000454.1) was obtained from NCBI. After searching for similarity among target sequences and homologues in the protein database using a fugue module, the crystal structure of UDP-glucosyltransferase GtfB (PDB code = 1IIR) was selected as the homology template. On the basis of this template, a backbone was constructed, as well as structurally-conserved regions (SCR) and models of variable regions of the structure. Finally, a three-dimensional model of UGT1A1 was obtained through following energy minimization optimization.
Using 
Results and discussion
Screening flavonoids for inhibition potentials against UGT1A1
In this study, to systematically explore the structure-inhibition relationships of flavones as UGT1A1 inhibitors, we have collected 56 flavones and assayed their inhibitory effects on the human UGT1A1, using a fluorescence-based biochemical assay [47] . Firstly, the inhibition potentials of all collected flavones against UGT1A1 catalyzing NCHN-O-glucuronidation were screened (Figure 1) , taking advantage of the high fluorescence intensity and UGT1A1-specificity of NCHN as glucuronidation substrate in HLM [47] . The results
revealed that most of the tested flavones inhibited UGT1A1-mediated NCHN-O-glucuronidation by 50% or more at the high concentration (Figure 1) . However, there were some compounds, such as 2, 4, 16 and 42, that did not have a significant effect. A unique exception within the current flavonoids collection was the result with 6-methoxyflavone, compound no. 10, that clearly activated UGT1A1 by about 2-fold ( Figure   1 ).
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After the first inhibition screen, the dose-inhibition curves of the flavonoids for UGT1A1
were depicted, using different inhibitor concentrations (Figures S2 to S6) , and the derived IC 50 values of all the tested flavonoids were listed in 3.9 μM) were more potent inhibitors of UGT1A1 than the positive control PPT (IC 50 = 6.5 μM). These findings demonstrate that many natural flavonoids can strongly inhibit the enzymatic activity of UGT1A1, suggesting that medicinal plants that are rich in flavonoids might trigger metabolic disorder of bilirubin metabolism via UGT1A1 inhibition.
Structure-inhibition relationships of flavonoids against UGT1A1
It appears from the results in Table 1 metabolic stability of these flavones, enhance their water solubility and could potentially reduce liver toxicity [64] [65] . It should also be added that flavonoid glycosides displayed very weakly inhibition on UGT1A1-mediated NCHN-O-glucuronidation, in comparison to the corresponding aglycones. These experimental data may be regarded as a proof of concept that to improve the metabolic stability and the safety profiles of some investigational new drugs (especially for flavonoid-type drug candidates) without strong UGT1A1 inhibition.
Inhibition mechanism
Considering that the wide distribution of acacetin and kaempferol in herbs or vegetables, as well as their strong inhibition of the human UGT1A1, we further investigated the inhibition mechanism of these two flavonoids toward UGT1A1. In this part, two highly specific florescent probes for UGT1A1, NCHN and NHPN, were used to explore the interactions of these two UGT1A1 inhibitors with the ligand-binding sites of UGT1A1, as well as to investigate their inhibition kinetics. Notably, a recent study has demonstrated that NCHN and NHPN may bind at different ligand-binding sites within UGT1A1, only one of them, the NHPN site, also binds bilirubin [47] . Thus, NCHN and NHPN could be used as site-specific makers for UGT1A1 ligands, at least for the two important ligand-binding sites we are currently certain about [47] . (Figure 4A & 4B) . Time-dependent inhibition assays demonstrated that in both cases the inhibition was not time-dependent (Figure S7 ), suggesting that kaempferol is also a reversible inhibitor of UGT1A1.
UGT1A1 Inhibition by acacetin
Lineweaver-Burk plots revealed that kaempferol functions as a noncompetitive inhibitor toward NCHN-O-glucuronidation in HLM (Figure 4C) . Unlike NCHN-O-glucuronidation,
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17 the inhibition of NHPN-O-glucuronidation in HLM by kaempferol was clearly competitive (Figure 4D) . The K i values of kaempferol were 1.74±0.29 µM and 0.68±0.24 µM for the inhibition of NCHN-and NHPN-O-glucuronidation reactions, respectively. These findings indicate that kaempferol is a particularly strong inhibitor of the human UGT1A1. Moreover, this compound binds at the NHPN binding site, also named the bilirubin-binding site. Hence, our findings suggest that uptake of kaempferol into the liver, so that its concentration will approach 0.4-0.5 µM, could start interfering with bilirubin conjugation, perhaps even leading to hyperbilirubinemia in some individuals, particularly those that have low expression level of the enzyme, as in the rather common Gilbert's Syndrome. Acacetin is a strong inhibitor of UGT1A1 as well, even if not as strong as kaempferol. It might be added that when considering the possible risks of these and other flavonoids for bilirubin glucuronidation by UGT1A1, one also has to consider the rates of detoxification and excretion of the flavonoids themselves, let alone their generally poor bioavailability [66] [67] [68] . More investigation on these topics should be done in the future to fully clarify their risk to humans.
Docking simulations
In 
Conclusion
